Close

Anti-HPV 16 E6 (YF96) TCR (HLA-A*0201/TIHDIILECV) Lentivirus Packaging Kit (XS-0622-YF194)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This kit provides a complete lentivirus packaging system to produce anti-E6 (YF96) TCR lentivirus, which enables TCR-T cells generation to target E6. It contains plasmids that express all the viral proteins necessary, and TCR detection reagent, providing a full set of reagents for TCR lentivirus packaging and TCR expression evaluation. The expressed anti-E6 TCR lentiviruses are HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells. These viruses constitutively express the TCR restricted to HLA-A*0201/TIHDIILECV(29-38). TCR detection reagent can be used to detect the positive expression rate of TCR-T cells after lentiviral transduction.

  Add to Cart

Description

  • Target
  • E6
  • Components
  • This kit contains a TCR lentiviral vector, packaging vectors, TCR detection reagent, and 293 cells.
    1. A TCR lentiviral vector
    • Anti-E6 (YF96) TCR plasmid
    2. Three packaging vectors
    • LentiArt™ pHelp1
    • LentiArt™ pHelp2
    • LentiArt™ pHelp3
    3. TCR detection reagent
    4. 293 cells
  • Size
  • 10 reactions; 20 reactions; 50 reactions
  • Storage Conditions
  • For details of the storage requirements, please see the User Manual for instructions.
  • Applications
  • TCR lentivirus packaging; TCR lentivirus transfection; TCR-T cell development; TCR-T cell therapy.

TCR Vector

  • MHC Allele
  • HLA-A*0201
  • Peptide
  • TIHDIILECV
  • Epitope
  • 29-38
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • TCR Construction
  • TCR alpha-P2A-TCR beta

Target

  • Gene Name
  • E6
  • Full Name
  • protein E6*;transforming protein E6
  • scFv
  • YF96
  • Host Species
  • Human
  • Target Species
  • HPV 16
  • Target Background
  • Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. Most HPV infections are subclinical and will cause no physical symptoms; however, in some people subclinical infections will become clinical and may cause benign papillomas (such as warts [verrucae] or squamous cell papilloma), premalignant lesions that will drive to cancers of the cervix, vulva, vagina, penis, oropharynx and anus. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases.
  • Synonyms
  • HPV; HPV16; E6
  • Related Disease
  • Melanoma

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-HPV 16 E6 (YF96) TCR (HLA-A*0201/TIHDIILECV) Lentivirus Packaging Kit (XS-0622-YF194). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.